The treatment Xultophy, which combines Novo Nordisk's long-acting insulin Tresiba with the GLP-1 analog Victoza, is now headed to the Chinese market.
In Wednesday's report for the third quarter of the year, Novo Nordisk reports that the Chinese health authority, China National Products Administration (NMPA), has approved of the injection therapy for type 2 diabetes.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.